Subsequent events (Tables) (Cangene [Member])

12 Months Ended

Dec. 31, 2013

Cangene [Member]

Business Acquisition [Line Items]

Estimated Purchase Price

The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at February 21, 2014.  As of the date of this filing, the valuation of acquired intangible assets, inventory, deferred taxes, property plant and equipment, contingent purchase consideration and other fair value adjustments are not complete, and as such the purchase price allocation is subject to change.

(in thousands)	February 21, 2014
Estimated fair value of tangible assets acquired and liabilities assumed:
Acquired tangible assets (i)	$	202,500
Assumed tangible liabilities		(38,300	)
Total estimated fair value of tangible assets acquired and liabilities assumed		164,200
Identified intangible assets		52,500
Deferred tax liability associated with identified intangible assets		(3,000	)
		49,500
Goodwill		8,300
Total preliminary estimated purchase price	$	222,000

(i) Acquired tangible assets reflect a $12.3 million adjustment to record inventory at fair value, referred to as a step-up adjustment. The $12.3 million step-up was estimated to be amortized through cost of product sales and contract manufacturing over the next five years based on estimated inventory turnover which, will increase costs of product sales during such period.

Intangible Assets Acquired

The table below summarizes the preliminary estimated fair value of intangible assets acquired and the estimated amortization periods:

			Amortization
			Period
($ in thousands)	Amount		in years
Corporate trade name	$	2,600		5.0
Marketed products		5,100		15.0
Licensed products		1,900		3.0
Biodefense		34,400		15.0
Contract manufacturing		8,500		15.0
Total identified intangible assets	$	52,500

Pro Forma Results

The following pro forma information is presented as if the acqusition had occurred on January 1, 2012, and combines the historical results of operations of the Company and Cangene for the years ended December 31, 2013 and 2012.

	December 31,
(in thousands, except per share data)	2013		2012
Pro forma revenue	$	440,320	$	400,269
Pro forma net income	$	13,914	$	2,171